The forgreotablets (90mg) developed by Stone Pharmaceutical Group have been approved by the State Drug Administration for registration of drugs
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Stone Pharmaceutical Group announced that its affiliatedcompany(http://stone pharmaceutical group, O'Italian Pharmaceutical Co., Ltddeveloped for the Grelo tablets (90mg) has been issued by the State Drug AdministrationDrug(http://registration approvala direct-acting, reversible combination of P2Y12 platelethttp://
inhibitors for the of
the of the of the of the of the of the of the of the of the of the of theCombined with aspirin, the incidence of cardiovascular death, myocardial infarction and stroke can be reduced in patients with acute coronary syndrome or in patients with a history of myocardial infarctionthe Grelo tablets have been recommended by several international treatment guidelines for the treatment of patients with acute coronary syndrome, with high clinical application value and good market prospectsAccording to the data, sales of end-of-the-grid tablets in key provinces and cities have grown rapidly in recent years, reaching 274 million yuan in 2018, up 68.84 percent year-on-year(http:// themanufacturer of Guerrero tablets,AstraZeneca and Sinatra, while AstraZeneca has a unique market shareStone Pharmaceuticals said the approval of the(http://of theproducts would further enrich the Group's product portfolio and contribute to the Group's development in the cardiovascular sector
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
